Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105117 · ClinicalTrials.gov registry record · Phase 4
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
A Phase 4 study of Pulmonary Arterial Hypertension, sponsored by Actelion.
- Completed
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
- 7
- Study locations
NCT01105117 is a Phase 4 study of Pulmonary Arterial Hypertension that has completed, run by Actelion. The registered enrollment target is 2 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (100% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT01105117, a Phase 4 study of Pulmonary Arterial Hypertension, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an open-label, non-randomized extension to study AC-066A401. The study will assess safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a means for continuing treatment after ending participation in study AC-0066A401.
Conditions Studied
Interventions
- DRUG ACT-385781A (Actelion Epoprostenol)
- DRUG Flolan®
Study Locations (7)
Texas
- University of Texas Southwestern Medical Center - Dallas
- Baylor College of Medicine - Houston
California
- University of California - San Diego - La Jolla
Colorado
- University of Colorado - Denver - Aurora
North Carolina
- Duke University Medical Center - Durham
Pennsylvania
- University of Pennsylvania-Penn Presybyterian Medical Center - Philadelphia
Tennessee
- Vanderbilt Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01105117
The ClinicalTrials.gov registry entry for NCT01105117 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (100% lower). The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which ACT-385781A (Actelion Epoprostenol) is the first listed.
NCT01105117 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Texas, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT01105117 about?
NCT01105117 is a clinical study titled "Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401". This is an open-label, non-randomized extension to study AC-066A401. The study will assess safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a means for continuing treatment after ending participation in study AC-0066A401.
What is the current status of trial NCT01105117?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2010-05. Estimated completion is 2011-12.
What conditions does trial NCT01105117 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT01105117?
The interventions under investigation include: ACT-385781A (Actelion Epoprostenol) (DRUG), Flolan® (DRUG).
Who is sponsoring clinical trial NCT01105117?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01105117 being conducted?
This trial has 7 study locations across California, Colorado, North Carolina, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 4
-
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 4
-
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
COMPLETED · Phase 4
-
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
COMPLETED · Phase 4
-
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
COMPLETED · Phase 4
-
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.